Lymphoma, T-Cell
Oncology·MeSH: Lymphoma, T-Cell, Cutaneous
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
3 drugs in development·3 companies·4 clinical trials
Drug Pipeline by Phase
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| pf-08046045 | PFIZER INC (PFE) |
Compare drugs
Frequently asked questions
How many drugs are in development for Lymphoma, T-Cell?
BioSniper tracks 3 drugs in development for Lymphoma, T-Cell across 3 companies.
How many clinical trials target Lymphoma, T-Cell?
There are 4 clinical trials targeting Lymphoma, T-Cell tracked by BioSniper.
What is the prevalence of Lymphoma, T-Cell?
The estimated prevalence of Lymphoma, T-Cell is approximately 56.0 per 100,000 population.
Deep-dive into Lymphoma, T-Cell
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis